IMA ImageneBio, Inc.
Price Chart
Executive Summary
ImageneBio reported its Q4 and full-year 2025 financial results, highlighting a strong cash position of $135.3 million post-merger and ongoing Phase 2b ADAPTIVE trial for IMG-007 in atopic dermatitis. While R&D spending decreased slightly, G&A expenses more than doubled due to merger-related and personnel costs, leading to a wider net loss. No revenue or earnings guidance was provided, and the company remains in clinical development with no near-term commercial catalysts.
Key Financial Metrics
Actionable Insight
The stock reaction is likely to be muted as the filing contains no clinical data readouts or near-term catalysts. Monitor upcoming SID meeting in May 2026 for preclinical data presentation and track enrollment progress in the ADAPTIVE trial for potential acceleration of the timeline.
Key Facts
- Ended 2025 with $135.3 million in cash, up from $12.1 million in 2024, due to a reverse merger and $75 million private placement.
- R&D expenses decreased to $3.3M in Q4 2025 from $3.8M in Q4 2024.
- G&A expenses rose to $5.2M in Q4 2025 from $2.4M in Q4 2024, driven by merger costs and stock-based compensation.
- Net loss widened to $6.9M in Q4 2025 from $4.8M in Q4 2024.
- Full-year 2025 net loss was $45.3M vs. $36.6M in 2024; license revenue declined to $800K from $3.5M.
- IMG-007 Phase 2b trial ongoing with topline data expected in 2027; protocol amendment submitted to expand dosing regimens.
- No safety concerns reported; no cases of pyrexia, ulcers, or malignancies observed.
Financial Impact
License revenue declined 77% YoY to $800K; full-year net loss increased 24% to $45.3M. Cash position strengthened to $135.3M, sufficient to fund operations into late-stage trials.
Risk Factors
- Clinical development risk: IMG-007 is still in Phase 2b with topline data not expected until 2027.
- Revenue concentration: License revenue dropped sharply from $3.5M to $800K, indicating reliance on non-core, one-time income sources.
- Increasing G&A costs: Rising administrative expenses post-merger could pressure cash runway if not managed.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252746 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 30, 2026
23d ago
|
DEFA14A
| — | awaiting T+20 | — | — |
|
Apr 13, 2026
5w ago
|
8-K
| $6.05 $5.61 | ▲ +7.27% | ▲ +15.00% | $5.56 (+8.10%) |
|
Apr 13, 2026
5w ago
|
Press Release
| $6.05 $5.61 | ▲ +7.27% | ▲ +15.00% | $5.56 (+8.10%) |
|
Apr 6, 2026
6w ago
|
EFFECT
| $4.55 $5.72 | ▲ +25.60% | ▲ +16.62% | $5.56 (+22.20%) |
|
Mar 17, 2026
9w ago
|
Press Release
| $5.83 $5.78 | ▼ −0.77% | ▼ −6.82% | $5.56 (−4.55%) |
|
Mar 10, 2026
10w ago
|
Press Release
| $6.07 $4.57 | ▼ −24.71% | ▼ −24.56% | $5.56 (−8.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access